UK markets close in 5 hours 34 minutes

argenx SE (ARGNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
357.000.00 (0.00%)
At close: 10:40AM EDT

argenx SE

Willemstraat 5
Breda 4811 AH
Netherlands
31 10 703 8441
https://www.argenx.com

Sector(s)
Industry
Full-time employees650

Key executives

NameTitlePayExercisedYear born
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MScCEO & Exec. Director1.28MN/A1972
Prof. Hans de Haard Ir, Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1960
Mr. Karl GubitzChief Financial OfficerN/AN/A1970
Mr. R. Keith WoodsChief Operating OfficerN/AN/A1968
Mr. Arjen Lemmen M.Sc.VP of Corp. Devel. & StrategyN/AN/A1985
Dr. David L. Lacey M.D.Advisor19.71kN/A1952
Ms. Andria WilkGlobal Head of QualityN/AN/A1974
Mr. Filip BorgionsVP & Global Head of Technical OperationsN/AN/AN/A
Ms. Beth DelGiaccoVP and Global Head of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Malini MoorthyGen. CounselN/AN/A1970
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Corporate governance

argenx SE’s ISS governance QualityScore as of 1 June 2022 is 8. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 3; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.